PFIZER will boost Dividend to $0.31-$0.32 in december= $1.28/ $22.35 =5.7% better than banks and safer with Dividend cut coming from Citigroup and other financials who need to raise Capital

LONG WE GO…

Pharma 2020: The vision Print-friendly version
Email to a colleague

Download Pharma 2020: The vision - Which path will you take? (711 kb)

http://www.pwc.com/Extweb/onlineforms.nsf/docid/FF67E81D9B77C916852572F200628F3B?opendocument

Which path will you take?

By 2020 the pharmaceutical market is anticipated to more than double to US$1.3 trillion, with the E7 countries — Brazil, China, India, Indonesia, Mexico, Russia and Turkey — accounting around for one fifth of global pharmaceutical sales. Further, incidence of chronic conditions in the developing world will increasingly resemble those of the developed world. But Pharma 2020: The vision - which path will you take? indicates that the current pharmaceutical industry business model is both economically unsustainable and operationally incapable of acting quickly enough to produce the types of innovative treatments demanded by global markets. In order to make the most of these future growth opportunities, the industry must fundamentally change the way it operates.

Some of the major changes PwC anticipates for the industry are:

Health care will shift in focus from treatment to prevention
Pharmaceutical companies will provide total health care packages
The current linear phase R&D process will give way to in-life testing and live licensing, in collaboration with regulators and health care providers
The traditional blockbuster sales model will disappear
The supply chain function will become revenue generating as it becomes integral to the health care package and enables access to new channels
More sophisticated direct-to-consumer distribution channels will diminish the role of wholesalers.